CERC-002

An anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes (part of the Tumor Necrosis Super Family 14)), fully human, monoclonal antibody

CERC-002

Targeting Severe Pediatric Onset Crohn’s Disease

CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes (part of the Tumor Necrosis Super Family 14)), fully human, monoclonal antibody being developed as a treatment for Pediatric Crohn’s Disease.


CERC-002

CERC-002 is currently enrolling patients in a Phase Ib Escalating Dose, Open-Label, Signal-Finding Study to Evaluate the Safety, Tolerability, and Short-Term Efficacy of the Anti-Light Monoclonal Antibody CERC-002 in Adults With Moderate to Severe Active Crohn's Disease Who Previously Failed Treatment With an Anti-TNFα Agent, With and Without Loss of Function Mutations in Decoy Receptor 3 (Anti-LIGHT in Anti-TNFα-Resistant Crohn's Disease [TRaCk LIGHT]). This is a precursor trial before going into Pediatric patients.

Attributes
of CERC-002

  • First in Class
  • Fully Human Monoclonal Antibody
  • Novel Free-LIGHT assay for biomarker-enabled development
  • Subcutaneous Dosing

About Pediatric Onset Crohn’s Disease

Pediatric Crohn’s disease is a rare, inflammatory bowel disease characterized by severe, chronic inflammation of the intestinal wall or any portion of the gastrointestinal tract. Common symptoms of pediatric Crohn’s disease are cramping, abdominal pain, and chronic episodes of watery diarrhea; blood may at times be seen in the diarrhea. In pediatric Crohn’s disease, the immune system responds to a stimulus or ‘trigger’, often an infection, but the response is abnormal. The immune system does not shut off as it is supposed to and instead mistakenly targets the gastrointestinal system, and the large and small intestines in particular. This sustained and abnormal immune system activity causes chronic inflammation and irritation of the tissues of the gastrointestinal tract, resulting in the signs and symptoms of pediatric Crohn’s disease.

Crohn’s disease is a common disorder, affecting as many as 780,000 people in the United States. The disorder is most common in individuals between 15-35, with approximately 25% diagnosed by age 20. The Crohn’s and Colitis Foundation of America estimates there may be as many as 80,000 children in the United States with IBD.